Articles

Idiopathic Castleman Disease: Clinical Features and Therapeutic Options

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Restoration of Health with Siltuximab in Multicentric Castleman Disease

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Siltuximab Efficacy in Multicentric Castleman’s Disease Is Independent of Baseline Symptom Burden

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Adding Rituximab to CHOP Improves Clinical Outcomes in Mantle-Cell Lymphoma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Long-Term Maintenance with Rituximab in Elderly Patients with Mantle-Cell Lymphoma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Antagonism of Immune Effector Function by Ibrutinib or Obinutuzumab versus Rituximab

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Ibrutinib Alone or in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Data from the SPARK Study: Mutational Analysis of Patients with Primary Resistance to Ibrutinib in Relapsed/Refractory Mantle-Cell Lymphoma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

International Research Agenda for Multicentric Castleman’s Disease

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Updates on Treatments for Castleman’s Disease

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Page 208 of 329